At 4.6% CAGR, the Europe Pharmaceutical Fluid Handling Market is projected to be worth US$ 3,792.49 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe pharmaceutical fluid handling market was valued at US$ 2,903.07 million in 2022 and is expected to reach US$ 3,792.49 million by 2028, registering a CAGR of 4.6% from 2022 to 2028.  Increasing drug production and growing adoption of single-use-systems (SUS) in the pharmaceutical industry are the critical factors attributed to the market expansion.

Pharmaceutical fluid handling is an integral part of the pharmaceutical industry to ensure that fluids such as cough syrups, intravenous products, and complex active pharmaceutical ingredients are delivered in a safe and timely manner. To succeed and be reliable, businesses need to utilize the correct handling equipment and instruments. The manufacturing divisions in the biotechnology & pharmaceutical industry require fluid control systems since most processes involve liquid such as feed media, buffer solutions, cell extracts, and product fractions. In recent years, research and development efforts have increased along with investments in developing innovative treatments. The increasing number of clinical trials, drug production, and increasing investments in R&D are contributing to the growth of the Europe pharmaceutical fluid handling market across the region.

On the contrary, high price of failed clinical trails hurdles the growth of Europe pharmaceutical fluid handling market.

Based on offering, the Europe pharmaceutical fluid handling market is segmented into equipment & solutions and services. The equipment segment held 83.9% market share in 2022, amassing US$ 2,434.23 million. It is projected to garner US$ 3,146.77 million by 2028 to expand at 4.4% CAGR during 2022–2028

Based on tubing, the Europe pharmaceutical fluid handling market is segmented into TPE, PVC, and silicon. The silicon segment held 54.2% market share in 2022, amassing US$ 1,573.54 million. It is projected to garner US$ 2,037.12 million by 2028 to expand at 4.4% CAGR during 2022–2028.

Based on application, the Europe pharmaceutical fluid handling market is segmented into fluid handling and management, fluid preparation, integration and automation, aseptic processing, buffer management, and others. The fluid handling and management segment held 32.7% market share in 2022, amassing US$ 948.56 million. It is projected to garner US$ 1,214.94 million by 2028 to expand at 4.2% CAGR during 2022–2028.

Based on usage, the Europe pharmaceutical fluid handling market is segmented into cough syrup, intravenous products, complex active pharmaceutical ingredients (APIs), and others. The intravenous products segment held 38.6% market share in 2022, amassing US$ 1,121.72 million. It is projected to garner US$ 1,515.42 million by 2028 to expand at 5.1% CAGR during 2022–2028.

Based on end user, the Europe pharmaceutical fluid handling market is segmented into biotechnology companies, pharmaceutical and medical companies, and others. The biotechnology companies segment held 48.4% market share in 2022, amassing US$ 1,405.30 million. It is projected to garner US$ 1,888.77 million by 2028 to expand at 5.1% CAGR during 2022–2028.

Based on country, the Europe pharmaceutical fluid handling market is segmented into Germany, UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 26.0% market share in 2022. It was assessed at US$ 754.22 million in 2022 and is likely to hit US$ 1,019.42 million by 2028, exhibiting a CAGR of 5.2% during the forecast period.    

Key players dominating the Europe pharmaceutical fluid handling market are Australian Fluid Handling Pty Ltd, CIRCOR International Inc, Danaher Corp, Fraser Ross Ltd, Merck KGaA, Parker Hannifin Corp, RAUMEDIC AG, Rochling SE & Co KG, Spirax Sarco Engineering plc, and Tef Cap Industries Inc, among others.  

• In 2021, Rigaku Corporation has acquired all issued shares of MILabs B.V.  on August 2, 2021, as part of their full-scale effort to enter the life sciences business. Through this acquisition, Rigaku will expand its life sciences modality business globally by combining MILabs’ multi-modality businesses, including PET, SPECT, Optical Imaging, and CT equipment for animals, with Rigaku's original X-ray imaging business for animals.

• In 2022, Watson-Marlow Fluid Technology Solutions (WMFTS) has launched BioPure Braided Hose assemblies as an end-to-end solution for companies requiring fitting, hose, assembly & testing.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com